Literature DB >> 32227680

Incorporating historical two-arm data in clinical trials with binary outcome: A practical approach.

Manuel Feißt1, Johannes Krisam1, Meinhard Kieser1.   

Abstract

The feasibility of a new clinical trial may be increased by incorporating historical data of previous trials. In the particular case where only data from a single historical trial are available, there exists no clear recommendation in the literature regarding the most favorable approach. A main problem of the incorporation of historical data is the possible inflation of the type I error rate. A way to control this type of error is the so-called power prior approach. This Bayesian method does not "borrow" the full historical information but uses a parameter 0 ≤ δ ≤ 1 to determine the amount of borrowed data. Based on the methodology of the power prior, we propose a frequentist framework that allows incorporation of historical data from both arms of two-armed trials with binary outcome, while simultaneously controlling the type I error rate. It is shown that for any specific trial scenario a value δ > 0 can be determined such that the type I error rate falls below the prespecified significance level. The magnitude of this value of δ depends on the characteristics of the data observed in the historical trial. Conditionally on these characteristics, an increase in power as compared to a trial without borrowing may result. Similarly, we propose methods how the required sample size can be reduced. The results are discussed and compared to those obtained in a Bayesian framework. Application is illustrated by a clinical trial example.
© 2020 The Authors. Pharmaceutical Statistics published by John Wiley & Sons Ltd.

Keywords:  clinical trials; historical data; power prior; sample size determination; type I error rate

Mesh:

Year:  2020        PMID: 32227680     DOI: 10.1002/pst.2023

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  1 in total

1.  Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials.

Authors:  Elias Laurin Meyer; Peter Mesenbrink; Cornelia Dunger-Baldauf; Ekkehard Glimm; Yuhan Li; Franz König
Journal:  Pharm Stat       Date:  2022-01-31       Impact factor: 1.234

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.